Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

Sarepta Therapeutics faces challenges as the FDA halts gene therapy trials for LGMD and revokes AAVrh74 platform designation.

US stocks rose on Monday, with fresh records for the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) in sight as Wall Street ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the August 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Investing.com -- Sarepta Therapeutics Inc (NASDAQ: SRPT) stock tumbled 10% following the announcement that the U.S. Food and Drug Administration has placed a clinical hold on the company’s ...

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics (NASDAQ:SRPT), presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 10, JPMorgan lowered its price target for Sarepta Therapeutics, Inc.